Complications and Side Effects of Botulinum Toxin for Cosmetic Use
Main Article Content
Abstract
Botulinum toxin, the causal agent of botulism, is employed in therapeutic settings for a number of purposes. Botulinum toxin injections address aesthetic issues induced or worsened by muscle contraction by controlling local neurotransmission. Therapy has a transient impact; muscle recovery is generally clinically visible a few months following treatment. Improper injection placement or toxin diffusion to unintended locations following injection might result in severe muscular weakening, which can cause temporary deformity or functional problems. Some aesthetic flaws, such as eyelid ptosis and a perplexing brow, can be corrected with therapeutic procedures. In other circumstances, progress is contingent on the botulinum toxin's declining action over time.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
I. Pavone, F., & Luvisetto, S. (2010). Botulinum neurotoxin for pain management: insights from animal models. Toxins, 2(12), 2890-2913.
II. Park, M. Y., & Ahn, K. Y. (2021). Scientific review of the aesthetic uses of botulinum toxin type A. Archives of Craniofacial Surgery, 22(1), 1.
III. Matarasso, S. L. (1998). Complications of botulinum A exotoxin for hyperfunctional lines. Dermatologic surgery, 24(11), 1249-1254.
IV. Carruthers, J., Fagien, S., & Matarasso, S. L. (2004). Consensus recommendations on the use of botulinum toxin type A in facial aesthetics. Plastic and reconstructive surgery, 114(6), 1S-22S.
V. Cox, S. E., & Adigun, C. G. (2011). Complications of injectable fillers and neurotoxins. Dermatologic Therapy, 24(6), 524-536.
VI. Wollina, U., & Konrad, H. (2005). Managing adverse events associated with botulinum toxin type A. American journal of clinical dermatology, 6(3), 141-150.
VII. Klein, A. W. (2002). Complications and adverse reactions with the use of botulinum toxin. Disease-A-Month, 48(5), 336-356.
VIII. Carruthers, A., & Carruthers, J. (2006). Advanced Cosmetic Use of Botulinum Toxin Type A. In Advanced Techniques in Dermatologic Surgery (pp. 39-58). CRC Press.
IX. Carruthers, J., & Carruthers, A. (2003). Aesthetic botulinum A toxin in the mid and lower face and neck. Dermatologic surgery, 29(5), 468-476.
X. Nestor, M. S., Han, H., Gade, A., Fischer, D., Saban, Y., & Polselli, R. (2021). Botulinum toxin–induced blepharoptosis: Anatomy, etiology, prevention, and therapeutic options. Journal of Cosmetic Dermatology, 20(10), 3133-3146.
XI. Magid, M., Finzi, E., Kruger, T. H. C., Robertson, H. T., Keeling, B. H., Jung, S., ... & Wollmer, M. A. (2015). Treating depression with botulinum toxin: a pooled analysis of randomized controlled trials. Pharmacopsychiatry, 25(06), 205-210.
XII. Baldo, B. A. (2016). Botulinum Neurotoxins. In Safety of Biologics Therapy (pp. 559-585). Springer, Cham.
XIII. Fan, T., Frederick, R., Abualsoud, A., Sheyn, A., McLevy-Bazzanella, J., Thompson, J., ... & Wood, J. (2022). Treatment of sialorrhea with botulinum toxin injections in pediatric patients less than three years of age. International Journal of Pediatric Otorhinolaryngology, 111185.
XIV. Rzany, B., Ascher, B., & Monheit, G. D. (2010). Treatment of glabellar lines with botulinum toxin type A (Speywood Unit): a clinical overview. Journal of the European Academy of Dermatology and Venereology, 24, 1-14.
XV. Naumann, M., Boo, L. M., Ackerman, A. H., & Gallagher, C. J. (2013). Immunogenicity of botulinum toxins. Journal of neural transmission, 120(2), 275-290.